A Phase II study for people with non-small cell lung cancer (NSCLC) that harbors a MET mutation and/or amplification
We are here to answer any questions you may have about participating in a Signature trial.
To learn whether capmatinib (INC280) displays safe and effective antitumor activity in treating NSCLC in patients who have received 1 or 2 prior systemic therapies for their advanced cancer.
You may be eligible to participate if you
Depending on the type of tumor you have and/or prior treatments, you may not be eligible for this clinical trial. Please speak to your doctor. This clinical trial may close at any time.